Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sab Biotherapeutics Inc WT (NQ: SABSW )

0.0400 -0.0102 (-20.32%)
Streaming Delayed Price Updated: 12:05 PM EDT, Jun 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,198
Open 0.0548
Bid (Size) 0.0350 (2)
Ask (Size) 0.1500 (10)
Prev. Close 0.0502
Today's Range 0.0400 - 0.0548
52wk Range 0.0100 - 0.1888
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
SAB Biotherapeutics Announces Departure of Chief Financial Officer
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics
This regulatory clearance enables clinical development of SAB-142 in patients with type 1 diabetes in the US 
From SAB Biotherapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+86.05%
+86.05%
1 Month
+33.33%
+33.33%
3 Month
+32.01%
+32.01%
6 Month
-2.68%
-2.68%
1 Year
-71.43%
-71.43%

More News

Read More
SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Provides SAB-142 Trial Update
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics to Present at INNODIA Annual Meeting
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics to Present at the BIO CEO & Investor Conference
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Announces Executive Leadership Change
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetes
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company Updates
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics to Present at Piper Sandler Healthcare Conference
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Appoints Michael G. King Jr. as Chief Financial Officer
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Approves Appointment of Andrew Moin to Board of Directors
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Provides Company Update for Q2 2023 Financial Results
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Presents Positive IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes at FOCIS 2023
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics to Present Novel Human IgG Platform with Positive Data and Breakthrough Therapy and Fast-Track Designations for Influenza Treatment at BIO 2023 International Convention
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.